Genmab A (GMAB) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Genmab A  (NASDAQ: GMAB)

Select the Financial Report: Select the Period:


Description of Genmab A's Business Segments
Genmab operates as a single operating segment and cash-generating unit (CGU). The recoverable amount of this CGU is estimated using a value in use (VIU) calculation based on net present value with an 8.6% discount rate over a 10-year forecast period. This period reflects the long-term nature of pharmaceutical development and commercialization, with no terminal growth rate applied. Key assumptions in the valuation include market share volume, pricing, new market development, and success rates for new products, which are influenced by external factors such as market competition and price regulation. Sensitivity analyses indicate that no impairment is required under reasonable changes to these assumptions. Research and development costs are expensed as incurred until regulatory approval is obtained or the probability of approval is established. Genmab does not recognize internally generated intangible assets from development activities but capitalizes licenses and rights acquired from third parties when criteria are met. Milestone payments increase the cost of capitalized licenses and rights. Acquired research and development projects and intellectual property rights are capitalized as intangible assets, reflecting the likelihood of future commercial sales. Goodwill arises from business combinations and is allocated to the single CGU representing Genmab's operating segment.

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.



Annual Report on Genmab A Divisions, Sales by Country

 
DARZALEX   DARZALEX Segment contribution to total sales 65.67 % of total Revenue
Kesimpta   Kesimpta Segment contribution to total sales 11.91 % of total Revenue
TEPEZZA   TEPEZZA Segment contribution to total sales 2.82 % of total Revenue
Other   Other Segment contribution to total sales 0.59 % of total Revenue
Janssen   Janssen Segment contribution to total sales 68.95 % of total Revenue
AbbVie   AbbVie Segment contribution to total sales 1.77 % of total Revenue
Roche   Roche Segment contribution to total sales 2.85 % of total Revenue
Novartis   Novartis Segment contribution to total sales 11.99 % of total Revenue
BioNTech   BioNTech Segment contribution to total sales 1.08 % of total Revenue
Pfizer   Pfizer Segment contribution to total sales 2.07 % of total Revenue
Royalties   Royalties Segment contribution to total sales 83.39 % of total Revenue
Net product Sales   Net product Sales Segment contribution to total sales 10.7 % of total Revenue
Reimbursement revenue   Reimbursement revenue Segment contribution to total sales 1.42 % of total Revenue
Milestone revenue   Milestone revenue Segment contribution to total sales 2.61 % of total Revenue
Collaboration revenue   Collaboration revenue Segment contribution to total sales 1.88 % of total Revenue
Excluding net product Sales   Excluding net product Sales Segment contribution to total sales 89.3 % of total Revenue
Denmark   Denmark Segment contribution to total sales 89.41 % of total Revenue
Netherlands   Netherlands Segment contribution to total sales 0.03 % of total Revenue
United States   United States Segment contribution to total sales 4.84 % of total Revenue
Japan   Japan Segment contribution to total sales 5.73 % of total Revenue


Twelve months ended 2025
GMAB s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
DARZALEX 2,443.00 65.67 %
Kesimpta 443.00 11.91 %
TEPEZZA 105.00 2.82 %
Other 22.00 0.59 %
Janssen 2,565.00 68.95 %
AbbVie 66.00 1.77 %
Roche 106.00 2.85 %
Novartis 446.00 11.99 %
BioNTech 40.00 1.08 %
Pfizer 77.00 2.07 %
Royalties 3,102.00 83.39 %
Net product Sales 398.00 10.7 %
Reimbursement revenue 53.00 1.42 %
Milestone revenue 97.00 2.61 %
Collaboration revenue 70.00 1.88 %
Excluding net product Sales 3,322.00 89.3 %
Denmark 3,326.00 89.41 %
Netherlands 1.00 0.03 %
United States 180.00 4.84 %
Japan 213.00 5.73 %
Total 3,720.00 100 %


Twelve months ended 2025
GMAB s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
Total 963.00 25.89 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
DARZALEX 21 % -
Kesimpta 37.15 % -
TEPEZZA -0.94 % -
Other -68.12 % -
Janssen 22.67 % -
AbbVie 13.79 % -
Roche -0.93 % -
Novartis 9.31 % -
BioNTech -68.5 % -
Pfizer 0 % -
Royalties 23.24 % -
Net product Sales 57.31 % -
Reimbursement revenue -63.19 % -
Milestone revenue -33.1 % -
Collaboration revenue 12.9 % -
Excluding net product Sales 15.83 % -
Denmark 15.97 % -
United States 37.4 % -
Japan 74.59 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.